COMMENTARY

Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development

February 23, 2016
“Humanitarian trials,” or the Japanese version of a compassionate use system, kicked off in January. Companies are allowed to decide whether they will conduct such trials, which relax protocols to allow the entry of patients who fail to meet criteria…

To read the full story

COMMENTARY

Takeda Pharmaceutical CEO Christophe Weber highlighted the importance of gaining a strong foothold in the world’s largest pharma market at…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…

By Takashi Ebisawa

On January 8, Japan’s biggest-ever outbound acquisition is expected to come to fruition, with London-listed Shire coming under the wing of Takeda Pharmaceutical. The Japanese major is paying £46 billion, or about 7 trillion yen, for the cash-and-stock deal, and…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…